HHS halts Eli Lilly’s single-drug COVID antibody treatment in U.S.; dual-drug alternative remains in...
By
Alicia Lasek
Mar 26, 2021
U.S. distribution of an infusion treatment using bamlanivimab only has been halted due to virus variant concerns, but an alternative antibody cocktail from the drugmaker can still be ordered, according...
LTC residents have detectable antibodies 6 months after COVID vaccination
By
Alicia Lasek
Apr 12, 2021
All residents tested in University of Pittsburgh Medical Center Senior Communities were found to have antibodies against SARS-CoV-2 after full vaccination. The findings are “cautious good news,”...
FDA OKs third antibody COVID therapy; variants spur new pause on another
By
Alicia Lasek
Jun 01, 2021
A new COVID-19 treatment made by GlaxoSmithKline now is the third monoclonal antibody therapy federally authorized to help prevent severe disease outcomes in high-risk patients. But gene variants are interfering...
U.S., Canada ‘not that different’ in LTC staff response to pandemic work conditions: study
By
Alicia Lasek
Feb 19, 2021
“We talk about how great Canada’s healthcare system is vis-à-vis that of the United States … but we are not that different when it comes to long-term care,” the researchers say.
Merck to seek emergency use for COVID-19 antiviral pill that cuts severe outcomes by 50 percent
By
Alicia Lasek
Oct 04, 2021
Molnupiravir has reduced COVID-19 deaths and hospitalizations by half in a new clinical trial. An orally delivered drug could offer unprecedented treatment convenience, the drug’s developers say.